BINEX Co., Ltd.

A053030

KR7053030003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
13,230 ^KRW	-0.60%		-12.67%	+47.82%

15/03	BINEX Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05/03	Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	MT

BINEX Co., Ltd. authorizes a Buyback Plan.

August 23, 2021

The Board of Directors of BINEX Co., Ltd. has authorized a buyback plan on August 23, 2021.

Latest news about BINEX Co., Ltd.

BINEX Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	05/03	MT
Sinjia Land Terminates Loan Deal With BINEX; Shares Up 6%	05/03	MT
Sinjia Land Scraps Deal to Buy Alternative Fuels Firm Over Unmet Closing Condition	02/01	MT
BINEX Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Sinjia Land Extends Long Stop Date to Acquire BINEX Singapore	30/22/30	MT
Sinjia Land Uses Portion of Proceeds from Share Placement for Deposit Payment to BINEX	01/22/01	MT
Singapore Shares End Week on High Note; Del Monte Pacific Shares Zoom 4% on Higher Fiscal Q4 Profit	24/22/24	MT
Sinjia Land to Make Refundable Deposit to BINEX in Relation to RTO Deal	24/22/24	MT
Sinjia Land to Acquire BINEX Singapore in RTO Deal	01/22/01	MT
With Investment Co., Ltd. acquired the remaining 16.63% stake in Rhinos Asset Management Co., Ltd from BINEX Co., Ltd..	01/21/01	CI
Exclusive: South Korea's GL Rapha to ship out 10 million Sputnik Light COVID-19 shots this month	14/21/14	RE
Boryung Pharmaceutical : S.Korea's GL Rapha to ship out 10 mln Sputnik Light COVID-19 shots this month	14/21/14	RE
Tranche Update on BINEX Co., Ltd.'s Equity Buyback Plan announced on August 23, 2021.	03/21/03	CI
BINEX Co., Ltd.'s Equity Buyback announced on August 23, 2021, has closed with 283,286 shares, representing 0.91% for KRW 5,532.99 million.	31/21/31	CI
BINEX Co., Ltd. announces an Equity Buyback for 283,286 shares.	23/21/23	CI
BINEX Co., Ltd. authorizes a Buyback Plan.	23/21/23	CI
An unknown buyer cancelled the acquisition of 6.97% stake in PeproMene Bio. Inc. from BINEX Co., Ltd..	11/21/11	CI
Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd.	22/21/22	CI
Noile-Immune Biotech Inc announced that it has received ¥999.998803 million in funding from BINEX Co., Ltd.	12/21/12	CI
BINEX Co., Ltd. announced that it has received KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.	06/20/06	CI
BINEX Co., Ltd. announced that it expects to receive KRW 50 billion in funding from Kiwoom Securities Co., Ltd., Aju IB Investment Co., Ltd., Kiwoom Private Equity, Inc.	28/20/28	CI
PharmAbcine Signs CMO Contract with Binex	02/20/02	CI
PharmAbcine Signs Long-Term Contract Manufacturing Organization Agreement for Olinvacimab with Binex	26/20/26	CI
Genexine : South Korea's Genexine begins human trial of coronavirus vaccine	19/20/19	RE

BINEX.CO.LTD is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal (GI) tract regulators and antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, as well as ointment, creams and others. It also manufactures bio medicines and raw materials. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BINEX CO., LTD.	+47.82%	30Cr
ELI LILLY AND COMPANY	+38.59%	73TCr
JOHNSON & JOHNSON	-7.89%	35TCr
MERCK & CO., INC.	+15.66%	33TCr
ABBVIE INC.	+0.24%	28TCr
ASTRAZENECA PLC	+13.47%	24TCr
NOVARTIS AG	+7.35%	21TCr
ROCHE HOLDING AG	-6.42%	20TCr
AMGEN INC.	+4.23%	16TCr
PFIZER, INC.	-1.70%	16TCr

Other Pharmaceuticals

BINEX Co., Ltd.

Equities

A053030

KR7053030003

Pharmaceuticals

BINEX Co., Ltd. authorizes a Buyback Plan.

Latest news about BINEX Co., Ltd.

Chart BINEX Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals